Eagle Pharmaceuticals, Inc. Contracts & Agreements

Amendment No. 1, dated as of December 2, 2024, to Rights Agreement, dated as of October 30, 2024, by and between Eagle Pharmaceuticals, Inc. and Equiniti Trust Company, LLC, as... (Filed With SEC on December 2, 2024)

Offer Letter, dated November 8, 2024, between Christopher Krawtschuk and the Company (Filed With SEC on November 12, 2024)

Rights Agreement, dated as of October 30, 2024 between Eagle Pharmaceuticals, Inc. and Equiniti Trust Company, LLC., which includes the form of Certificate of Designation as... (Filed With SEC on October 31, 2024)

Third Amendment to Third Amended and Restated Credit Agreement, among Eagle Pharmaceuticals, Inc., as borrower, JPMorgan Chase Bank, N.A., as administrative agent, and the lenders... (Filed With SEC on May 15, 2024)

Separation Agreement dated March 8, 2024 (Filed With SEC on March 8, 2024)

Offer Letter dated March 8, 2024 (Filed With SEC on March 8, 2024)

Second Amendment to Third Amended and Restated Credit Agreement, among Eagle Pharmaceuticals, Inc., as borrower, JPMorgan Chase Bank, N.A., as administrative agent, and the... (Filed With SEC on March 1, 2024)

Limited Waiver and First Amendment to Third Amended and Restated Credit Agreement, among Eagle Pharmaceuticals, Inc., as borrower, JPMorgan Chase Bank, N.A., as administrative... (Filed With SEC on January 16, 2024)

Offer Letter, by and between the Company and Michael Graves, dated December 21, 2023 (Filed With SEC on December 22, 2023)

Separation Agreement dated November 27, 2023 (Filed With SEC on November 29, 2023)

Settlement Agreement, by and between the Registrant, Teva Pharmaceuticals International GmbH, Cephalon, LLC, Dr. Reddys Laboratories, Ltd. and Dr. Reddys Laboratories, Inc., dated... (Filed With SEC on April 10, 2023)

Amendment to Development and Licensing Agreement, by and between the Company and Robert One, LLC, dated December 9, 2022 (Filed With SEC on December 14, 2022)

Amended and Restated Severance Benefit Plan, effective as of December 9, 2022 (Filed With SEC on December 9, 2022)

Settlement and License Agreement, by and between Teva Pharmaceuticals International GmbH (Filed With SEC on November 9, 2022)

Guaranty Agreement to Loan Agreement, by and among the Registrant, Acacia Pharma Limited and Cosmo Technologies Ltd., dated June 9, 2022 (Filed With SEC on August 9, 2022)

Securities Purchase Agreement, by and between the Registrant and Enalare Therapeutics Inc., dated August 8, 2022 (Filed With SEC on August 9, 2022)

Security Purchase Option Agreement, by and between the Registrant, Enalare Therapeutics Inc. and the other parties thereto, dated August 8, 2022 (Filed With SEC on August 9, 2022)

Announcement, dated March 28, 2022 (Filed With SEC on March 28, 2022)

Co-operation Agreement, dated March 27, 2022, by and between Eagle Pharmaceuticals, Inc. and Acacia Pharma Group plc (Filed With SEC on March 28, 2022)

Form of Shareholder Undertaking (Filed With SEC on March 28, 2022)

Form of Director Undertaking (Filed With SEC on March 28, 2022)

Lock-up Agreement, dated March 27, 2022, by and between Eagle Pharmaceuticals, Inc. and Cosmo Pharmaceuticals N.V (Filed With SEC on March 28, 2022)

Form of Shareholder Lock-up Agreement (Filed With SEC on March 28, 2022)

License Agreement, dated as of August 6, 2021, between the Registrant and AOP Orphan Pharmaceuticals GmbH (Filed With SEC on November 9, 2021)

License Agreement, dated as of August 19, 2021, between the Registrant and Combioxin SA (Filed With SEC on November 9, 2021)

Form of Performance Stock Unit Grant Package (2014 Equity Incentive Plan) (Filed With SEC on March 5, 2021)

Consulting Agreement between (Filed With SEC on November 2, 2020)

Co-Promotion Agreement, dated January 7, 2020, between the Registrant and Tyme Technologies Inc (Filed With SEC on May 11, 2020)

Co-Promotion Agreement with Tyme Technologies, Inc., dated January 7, 2020 (Filed With SEC on March 2, 2020)

Settlement Agreement, by and between the Registrant and Eli Lilly and Company, dated December 13, 2019 (Filed With SEC on March 2, 2020)

Fifth Amendment to Lease Agreement between the Registrant and CAPSTONE TICE BLVD LLC. dated as of August 8, 2019 (Filed With SEC on March 2, 2020)

Description of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 2, 2020)

Securities Purchase Agreement, dated January 7, 2020, between the Company and Tyme (Filed With SEC on January 8, 2020)

Eagle Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan (Filed With SEC on December 16, 2019)

Fourth Amendment to the Exclusive License Agreement, dated April 12, 2019, by and between Eagle Pharmaceuticals, Inc., a Delaware corporation and Teva Pharmaceuticals... (Filed With SEC on May 7, 2019)

Separation Agreement by and between the Registrant and Steven L. Krill, dated February 19, 201 (Filed With SEC on May 10, 2018)

Form of Performance Stock Unit Grant Package (2014 Equity Incentive Plan) (Filed With SEC on February 26, 2018)

Form of Restricted Stock Unit Grant Package (2014 Equity Incentive Plan) (Filed With SEC on February 26, 2018)

Amendment No. 1 to Stock Purchase Agreement, dated as of February 8, 2018 (Filed With SEC on February 14, 2018)

Separation Agreement dated January 24, 2018 (Filed With SEC on January 30, 2018)

Product Collaboration and License Agreement, by and between the Registrant and SymBio Pharmaceuticals Limited, effective as of September 19, 2017 (Filed With SEC on November 8, 2017)

[SIGNATURE PAGE FOLLOWS] (Filed With SEC on March 15, 2017)

CREDIT AGREEMENT dated as of January 26, 2017 among EAGLE PHARMACEUTICALS, INC. The Lenders Party Hereto and JPMORGAN CHASE BANK, N.A. as Administrative Agent JPMORGAN CHASE BANK,... (Filed With SEC on March 15, 2017)

STOCK PURCHASE AGREEMENT BY AND AMONG EAGLE PHARMACEUTICALS, INC. (as Buyer), ARSIA THERAPEUTICS, LLC (the Seller), ARSIA THERAPEUTICS, INC. (the Company), AMY SCHULMAN (solely in... (Filed With SEC on November 14, 2016)

CO-PROMOTION AGREEMENT (Filed With SEC on February 29, 2016)

LICENSE AGREEMENT (Filed With SEC on February 29, 2016)

EAGLE PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) (Filed With SEC on December 21, 2015)

* * * (Filed With SEC on December 21, 2015)

AMENDMENT TO THE EAGLE PHARMACEUTICALS, INC. 2007 INCENTIVE COMPENSATION PLAN (Filed With SEC on December 21, 2015)

AMENDMENT NO. 2 TO DEVELOPMENT AND LICENSING AGREEMENT (Filed With SEC on August 11, 2015)

AMENDMENT NO. 4 TO DEVELOPMENT AND LICENSING AGREEMENT (Filed With SEC on August 11, 2015)

EAGLE PHARMACEUTICALS, INC. OFFICER SEVERANCE BENEFIT PLAN APPROVED BY THE BOARD OF DIRECTORS: AUGUST 4, 2015 (Filed With SEC on August 10, 2015)

APPENDIX A EAGLE PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: NOVEMBER 21, 2013 APPROVED BY THE STOCKHOLDERS: JANUARY 26, 2014 IPO DATE:... (Filed With SEC on August 10, 2015)

SETTLEMENT AND LICENSE AGREEMENT (Filed With SEC on May 15, 2015)

EXCLUSIVE LICENSE AGREEMENT between EAGLE PHARMACEUTICALS, INC. and CEPHALON, INC. dated February 13, 2015 (Filed With SEC on May 15, 2015)

1,320,276 Shares Eagle Pharmaceuticals, Inc. Common Stock PURCHASE AGREEMENT (Filed With SEC on March 17, 2015)

EMPLOYMENT AGREEMENT (Filed With SEC on January 28, 2014)

[ ] Shares Eagle Pharmaceuticals, Inc. Common Stock PURCHASE AGREEMENT (Filed With SEC on January 28, 2014)

EAGLE PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: , 201 APPROVED BY THE STOCKHOLDERS: , 201 IPO DATE: , 201 (Filed With SEC on January 22, 2014)

EAGLE PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on January 22, 2014)

EAGLE PHARMACEUTICALS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: , 201 APPROVED BY THE STOCKHOLDERS: , 201 (Filed With SEC on January 22, 2014)

SUPPLY AGREEMENT (Filed With SEC on December 20, 2013)

DATED 14 DECEMBER 2012 AGREEMENT FOR THE SUPPLY OF ARGATROBAN AND TOPOTECAN between CIPLA LIMTED and EAGLE PHARMACEUTICALS, INC. (Filed With SEC on December 20, 2013)

SUPPLY AND DISTRIBUTION AGREEMENT (Filed With SEC on December 20, 2013)

DEVELOPMENT AND LICENSE AGREEMENT (Filed With SEC on December 20, 2013)

LICENSE AND DEVELOPMENT AGREEMENT (Filed With SEC on December 20, 2013)

LICENSE AND SUBLICENSE AGREEMENT BETWEEN LYOTROPIC THERAPEUTICS, INC. AND EAGLE PHARMACEUTICALS, INC. (Filed With SEC on December 20, 2013)

DEVELOPMENT AND LICENSE AGREEMENT (Filed With SEC on December 20, 2013)

SHORT FORM LEASE Between MACK-CALI CHESTNUT RIDGE L.L.C., as Landlord, and EAGLE PHARMACEUTICALS, INC., as Tenant Building: 50 Tice Boulevard, Woodcliff Lake, New Jersey (Filed With SEC on December 20, 2013)

David Riggs (Filed With SEC on December 20, 2013)

EAGLE PHARMACEUTICALS, INC. 2007 INCENTIVE COMPENSATION PLAN (Filed With SEC on December 20, 2013)

EAGLE PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on December 20, 2013)

EAGLE PHARMACEUTICALS, INC. THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (Filed With SEC on December 20, 2013)

Category

Industry

Companies

Contracts

Eagle Pharmaceuticals, Inc. Contracts & Agreements